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Abstract
Background: The incidence of pregnancy-associated breast cancer (PABC) is increasing, especially in the developed countries. 
Herein, we report the long-term outcomes of PABC from a single institution in an Arab country
Methods: Consecutive patients diagnosed to have PABC between 2005 and 2012 at a tertiary referral hospital from a Gulf 
Cooperation Council country were the subjects of the study. Long-term outcomes are reported, with a minimum follow-up of 8 years. 
Results: A total of 16 patients were evaluable for long-term survival analysis. The median age at the time of diagnosis was 31.5 (26-
40) years. Nine (56%) patients were multiparous (> 5 previous pregnancies). The mean gestational age at diagnosis was 19.7±7.4 
weeks. Immunohistochemistry revealed the following phenotypes: Luminal A 3 (18.8%); HER-2 enriched 8 (50%); triple-negative 5 
(31.2%). Three patients underwent modified radical mastectomy as the initial treatment, of which 2 received adjuvant chemotherapy 
during pregnancy. All other patients received either neoadjuvant or palliative chemotherapy during chemotherapy. The response rate 
was 75% (pCR 2; CR 1; PR 6). After a median follow-up of 60 months, median progression-free survival was 36 months (95%CI 
24.2 to 47.8), while the overall survival was 59 months (95%CI 31.6 – 86.4). Age, marker status, Ki-67 score, clinical stage and 
differentiation grade did not affect the PFS or OS on an univariate analysis.
Conclusion:  Fifty percent of the patient with PABC expressed HER-2/neu protein, and 1/3rd had triple-negative disease. The rate 
of response to chemotherapy, and long-term survival may help to set a benchmark for studies from the region. Larger cohort studies 
may help to draw firm conclusions.
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INTRODUCTION
Pregnancy-associated cancer (PAC) is defined as cancer 
diagnosed during pregnancy or within one year post-
partum. PAC constitutes 0.07% to 0.1% of all cancers 
[1]. Breast cancer is the most common PAC, followed 
by carcinoma of the cervix, lymphoma, leukemia, 
melanoma, and ovarian cancer [1]. The incidence 
of breast cancer during pregnancy is reported to be 
between 1:3,000 – 1:10,000 pregnancies [2]. Between 
0.2% – 3.8% of all breast cancers occur co-incidentally 
with pregnancy [2]. More than 90% of patients with 
pregnancy-associated breast cancer (PABC) present 
with a palpable mass, and is self-reported by patients. 
Less frequently, patients present with erythema, breast 
swelling, bloody nipple discharge, or local or distant 
metastasis [3]. The prevalence of PABC has been shown 
to be increasing with increasing maternal age, especially 
in the developed countries [4, 5]. 
The treatment of breast cancer is multi-modal and 
often involves surgery, sometimes with radiotherapy, 
systemic chemotherapy, and hormone therapy. PABC 
is unusual, and not many surgeons, obstetricians and 
oncologists have only limited, if any, experience in the 
management of cancer during pregnancy. An average 
obstetrician would see 2-3 cases in a 40-year career 
[1]. For several years, treatment of breast cancer and 
continuation of pregnancy were considered mutually 
exclusive. However, with the experience in the past few 
years with the use of cytotoxic chemotherapy, in the 
second and the third trimester, it is possible to continue 
with the pregnancy and the systemic treatment in almost 
all cases [6]. 
Whereas there is a plethora of data on the incidence, 
management and outcomes of PABC from the 
developed world, there are very little data from the 
developing countries, especially the middle-east, where 
the demographic features of breast cancer are different. 
For example, the mean age at the time of diagnosis of 
breast cancer in Oman is 47 years, and almost one-
third of these patients are in the child-bearing (less 
than 40 years) age [7]. On the other hand, the fertility 
rate is high, and the mean number of pregnancies 
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in the country is more than 78. It is plausible to think 
that PABC maybe even more common in developing 
countries. Previously, we reported the clinical features 
at presentation, response to treatment and short–term 
outcomes of patients and infants [8, 9]. Herein, we 
report the incidence, and long-term outcomes of patients 
treated for PABC at our institution. 
PATIENTS AND METHODS
Consecutive patients diagnosed to have PABC at 
a tertiary referral center for cancer diagnosis and 
treatment in Oman between Jan 2005 and Dec 
2012 were included. The database was searched to 
identify all cases. The number of deliveries in the unit 
of obstetrics during the time-period was also noted. 
Demographic information including the age at diagnosis 
of breast cancer, gravidity, gestational age at the time of 
diagnosis (assessed both by the last menstrual period 
and the ultrasound) were recorded. Histopathological 
features, such as the histological subtype, degree of 
differentiation, estrogen receptor (ER) expression, 
progesterone receptor (PgR) expression, HER-2/neu 
status (using either immunohistochemistry or fluorescent 
in-situ hybridization) and the proliferative marker Ki-67 
were also recorded. Before commencing the treatment, 
an X-ray of the chest, ultrasound of the abdomen, 
and blood tests including alkaline phosphatase were 
carried out, to clinically stage the disease, as accurately 
as was possible. Patients with clinically localized or 
locally advanced disease were treated according to the 
situation and preferences, either with surgery first or with 
neoadjuvant chemotherapy. Patients with metastatic 
disease at the time of presentation were treated with 
palliative chemotherapy. The time and mode of delivery 
were also recorded. After delivery, breast cancer was 
staged using a CT scan of the chest, abdomen and 
pelvis, and a 99Tc bone scan. Further treatment was 
continued according to the clinical stage, and the 
presence of predictive markers, such as ER, PgR, 
and HER-2/neu. Progression-free survival (PFS) was 
calculated using the method of Kaplan and Meier from 
the time of diagnosis to progression or death. Overall 
survival (OS) was calculated from the time of diagnosis 
to death or 31st Dec, 2020.
RESULTS
Over the study period, a total of 17 patients were 
diagnosed to have PABC. One patient was diagnosed 
to have ductal carcinoma in situ and was excluded 
from the overall analysis. This patient was 31 years at 
the time of diagnosis, was pregnant a 2nd time, and the 
gestational age at diagnosis was 10 weeks. The patient 
was treated with mastectomy, and after the delivery, was 
commenced on Tamoxifen.
Over the study period of 8 years, a total of 21,717 
deliveries were recorded in the obstetrical unit of the 
hospital, of which 16, coincided with the diagnosis 
of infiltrating carcinoma of the breast, suggesting an 
incidence rate of 0.00074 breast cancer cases per 
pregnancy. 
The median age at the time of diagnosis for the evaluable 
16 patients was 31.5 (26-40) years. The mean number 
of pregnancies before the diagnosis of PABC was 4.8 
(1-9); 9 (56.3%) patients had been pregnant 5 or more 
times before the pregnancy. All patients were diagnosed 
during pregnancy. The gestational age at the time of 
diagnosis was 19.7 (6-31) weeks. The details, including 
the mean tumor size, and the degree of differentiation 
are shown in Table 1. The predictive and prognostic 
markers are also shown in Table 1. Three patients 
(18.8%) were positive both for ER and PgR and negative 
for HER-2/neu (Luminal A). On the other hand 5 patients 
(31.2%) were triple-negative, whereas 8 patients had 
HER-2 enriched type breast cancer with or without co-
expression of ER and PgR. 
The details of the treatment are shown in Table 2. Out 
of the 16 evaluable patients, one patient presented 
with metastatic disease and was treated with palliative 
chemotherapy. Three patients underwent modified 
Table 1: Clinico-pathological features at presentation.
Median age at the time of diagnosis 31.5 (26-40) years
Gravidity 4.8 ± 2.3
Gestational age at diagnosis 19.7 ± 7.4 weeks
Clinical stage at diagnosis
Locally advanced 15
Metastatic 1







Luminal A 3 (18.3%)
HER-2 enriched 8 (50%)
Triple negative 5 (31.2%)
Table 2: Individual patient data on presentation, treatment, response to treatment and clinical stage.
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radical mastectomy (MRM) as the initial treatment; 2 
received adjuvant chemotherapy during the pregnancy, 
while one patient refused further treatment. Twelve 
patients received neoadjuvant chemotherapy, as shown 
in the table. 
During the pregnancy, patients received between 1 and 
8 cycles of chemotherapy, with a median of 4 cycles. 
(3 patients = 8 cycles, all including anthracyclines 
and taxanes; 1 patient = 6 cycles of FEC, 7 patients 
= 4 cycles, all including anthracyclines; 1 patients = 
3 cycles; 1 patient = 1 cycle). Of the 12 patients who 
received neoadjuvant chemotherapy during pregnancy, 
one patient was subsequently found to have the 
metastatic disease after delivery, and was continued on 
palliative chemotherapy, and did not undergo surgery. 
However, she had a partial response to chemotherapy 
during pregnancy. Of the 11 other patients, 2 achieved a 
pathological complete remission (pCR), one patient had 
a complete clinical remission (CR), 5 patients achieved 
a partial response (PR), whereas, 3 patients had stable 
disease (SD). The overall response rate (ORR) was 75%. 
No patient progressed while receiving chemotherapy.
Following delivery, patients were staged formally with 
a CT scan of the chest and the abdomen, and a bone 
scan. Overall 3 patients were found to have stage IV 
disease. One patient had pulmonary, hepatic and 
skeletal metastases, one had hepatic and skeletal 
metastasis, while one patient had a solitary lesion in the 
liver, which was treated with radiofrequency ablation, 
followed by further chemotherapy. The final pathological 
stage and further treatment after the delivery are also 
shown in Table 2. 
The mean gestational age at delivery was 35.6 ± 1.6 
weeks. The mean APGAR score at 1 and 5 minutes was 
8.7 ± 0.9 and 9.5 ± 0.9 respectively. All pregnancies and 
deliveries were uneventful except one patient who had 
intrauterine growth retardation (IUGR). For this patient, 
the gestational age at delivery was 34 weeks, and 
the APGAR scores at 1 and 5 minutes were 6 and 8 
respectively
Two patients developed pregnancy subsequent to the 
treatment and delivered healthy babies.
After a median follow-up of 60 months, median 
progression-free survival was 36 months (95% CI 24.2 














3 10 12 x 10 cm ACx4>Docx4 MRM pCR 0 0 ypT0N0M0 -
4 31 Multifocal ACx1 MRM CR 3mm 0 ypT1aN0M0 ACx3>Docx4 Trastuzumab








7 24 10 cm No Chemotherapy during pregnancy -
Not
evaluable xx xx
Stage IV Doc+Capx 3>
Doc+ Ctxx2
8 12 10 cm ACx4>Docx4 MRM PR 3 3/17 ypT2N1M0 Trastuzumab Tamoxifen
9 24 Multicentric ACx4 MRM SD 6 cm 5/27 ypT3N2M0 Pacliaxelx12w + Carboplatin
10 21 Multicentric ACx4 - PR xx xx Stage IV Docetaxel x 4 Trastuzumab
11 19 Multicentric MRMFECx4>Docx2 Not evaluable 2.6 6/24 pT2N2M0 Doc x 2
12 25 Multifocal ACx3 MRM SD 5.2 x 4.3 13/17 ypT3N3M0 ACx1>Docx4Trastuzumab
13 8 10 cm FECx6 MRM pCR In-situ 0 ypTisN0M0 -




15 24 8x8 cm ACx4 MRM SD 7cm 13/17 ypT3N3M0 PaclitaxelRadiotherapy
16 29 4 cm cm MRM - Not evaluable 2.5 39/42 pT2N3M0 Did not agree for further  Treatment
GAD = Gestational age at Diagnosis; MRM = Modified Radical Mastectomy; AC = Doxorubicin 60mg/m2 + Cyclophosphamide 600mg/m2; 
Doc = Docetaxel 75mg/m2; EC = Epirubicin 90mg/m2 + Cyclophosphamide 600mg/m2; FEC = 5Fluorouracil 500mg/m2 + Epirubicin 75mg/
m2 + Cyclophosphamide 500mg/m2; WLE+AC = Wide local excision + Axillary Clearance; PR = Partial response; pCR = Pathological complete 
Response; CR = Complete Response; SD = Stable disease; RFA = Radiofrequency Ablation; VNB+Cap = Vinorelbine + Capecitabine; Doc+Cap 
= Docetaxel + Capecitabine; Doc+Ctx = Docetaxel + Cyclophosphamide.
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- 47.8 months) while the overall survival for the entire 
cohort was 59 months (95% CI 31.6 – 86.4). Five-year 
PFS was 31%, whereas OS was 50% at 5 years and 
27% at 10 years (Figs. 1A&1B). On univariate log-rank 
analysis, age, marker status, Ki67 score, clinical disease 
stage and differentiation grade did not affect the PFS or 
OS significantly.
DISCUSSION
The aims of this retrospective analysis were two-fold. 
First of all, to report on the outcomes of PABC from Oman, 
a developing country, situated in the east of the Arabian 
Peninsula. Whereas there is a plethora of literature on 
the outcomes of PAC from the Western world, there are 
only a handful of reports from the developing countries, 
some of which are relatively old, and reported on 
very few women treated with the current standards of 
management [10, 11]. The second aim was to report the 
long-term outcomes of patients with PABC treated at 
a single institution on uniform clinical pathways, using 
modern chemotherapeutic agents, including taxanes.
Overall, the occurrence of cancer during pregnancy 
is not common and the incidence ranges between 
0.07 – 0.1 of all malignant tumors [1]. However, more 
recently, an increase in the incidence of PABC from 16 
to 37.4 per 100,000 deliveries has been observed [4, 
12]. The reason for the increasing incidence, at least in 
the western world, is the trend to delay pregnancy into 
later reproductive years. However, the same may not 
be true for developing countries, and countries with a 
high fertility rate. Although the median age at the time 
of diagnosis (31.5 years) in our series is comparable to 
what has been reported from Jordan [11], Saudi Arabia 
[10], the United States [13, 14], and Europe [15, 16]. 
However, in our series, the majority of women were 
multiparous, and 9/16 women were pregnant a 5th or 
more times when the breast cancer coincided with the 
pregnancy. This observation may be explained by the 
high fertility rate in Oman, estimated to be 7.12 births in 
ever-married women [8]. A total of 21,717 deliveries were 
recorded at our institution over the 8 years, of which 16, 
coincided with the diagnosis of infiltrating carcinoma of 
the breast, suggesting an incidence rate of 7.4 x 10-4. 
This is in comparison with the study from New South 
Wales, Australia [5]. Using a population-based cohort 
study design, the authors reported 1798 new cases of 
cancer in 1,309,501 maternities over a 15 year period, 
of whom 499 were diagnosed during pregnancy, and 95 
had breast cancer, giving an incidence rate of PABC to 
be one magnitude of order lower at 7.25 x 10-5. 
The protective effect of a full-term pregnancy on breast 
cancer, and further protection by additional pregnancies 
is well known [17]. However, the biology of PABC may 
be different from non-PABC. For example, there were 
important biological differences in this series, when 
compared to breast cancer in Oman in general [7]. All 
patients in the current series presented with either locally 
advanced or metastatic disease, compared to 54%, who 
had presented with stage III/IV disease in the period 
2003-2008. The tumor size ranged between 4 and 14 
cm, almost half of the patients had a multifocal disease. 
Fifty percent of patients had grade III infiltrating ductal 
carcinoma, compared to 35% in the general population. 
The proportion of patients with HER-2 positive disease 
was especially high (50%, compared to 21.3%), and 
almost 1/3rd of the patients had a triple-negative disease, 
compared to 15%.
There are conflicting reports on the impact of pregnancy 
on the biological features of breast cancer. On the one 
hand, Azim et al. compared 65 patients with PABC 
with twice the number of non-PABC patients matched 
for age, year of diagnosis, stage and neo-adjuvant 
chemotherapy, and did not find any significant differences 
in tumor characteristics between the two groups [18]. 
Fig. (1A): Progression-free survival of 16 patients treated for 
pregnancy-associated breast cancer. After a median follow up of 60 
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Fig. (1B): Overall survival of 16 patients treated for pregnancy-
associated breast cancer. After a median follow up of 60 months, 
median OS was 59 months (95% CI 31.6 – 86.4 months. 5-year OS 
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On the other hand, there are several reports that PABC 
may be associated with aggressive biological features. 
For example, Genin et al. compared the biological 
characteristics of 41 PABC with 241 non-PABC in 
women aged 43 or less [19]. The tumors were twice 
more likely to be larger (T3 or T4), express HER-2/neu 
protein, and were hormone receptor-negative. Murphy 
et al. compared 99 patients with PABC with twice the 
number of non-PABC, matched for age and the year of 
diagnosis [20]. Patients with PABC were more likely to 
have larger tumor size at presentation, a higher tumor 
grade, more nodal involvement, and to be negative 
for ER, and PgR. However, there was no significant 
difference in the OS. Pilewskie et al. used a slightly 
different definition of PABC, and included patients up to 
2 years after the pregnancy [21]. Patients with PABC, 
using this definition were more likely to have grade 3 
tumors, positive lymph nodes and triple-negative tumors 
compared to 114 nulliparous women.
Just as the data on the biological features of PABC 
is conflicting, the outcomes are also variable. For 
example, Murphy et al. showed that although PABC was 
biologically more aggressive, there was no significant 
difference in the OS20. On the other hand, Moreira et al. 
compared the outcomes of 87 patients with PABC with 
pairwise matched controls and showed that the median 
OS and the 5 and 10-year survival were significantly 
shorter for patients with PABC, and concluded that 
pregnancy was an independent poor prognostic factor 
in addition to tumor size, grade and stage [22]. Ali 
et al. compared 40 patients with 40 matched controls 
and demonstrated a significantly inferior DFS and OS 
for patients with PABC [14]. Johansson et al. using a 
population-based cohort study and a slightly different 
definition of PABC (including patients up to 2 years post-
partum), compared the outcomes of 1,110 patients with 
PABC with non-PABC, aged between 15-44 years, and 
showed an inferior long-term survival of patients with 
PABC [23]. A meta-analysis consisting of 30 studies, 
including 3,628 cases and 37,100 controls reported 
on the survival of PABC [24]. Controls were either 
matched or were selected either from the hospital or the 
population. The primary outcome measure was 1 year 
OS and the secondary end-point was 1 year DFS after 
the diagnosis and treatment of PABC. Overall, patients 
with PABC had a higher risk of death compared to the 
controls [24]. On the other hand, a more recent meta-
analysis of 54 studies showed that PABC was associated 
with a poor prognosis for OS, DFS, and causes specific 
survival. Heterogeneity in terms of the relationship of 
time of diagnosis with pregnancy was suggested to 
be an important factor, and the authors argued that 
the definition of PABC should be extended to include 
patients diagnosed up to 6 years postpartum [25]. 
The outcomes of patients diagnosed and treated 
during pregnancy or in the post-partum period are also 
beginning to emerge. For example, in the meta-analysis, 
the difference in survival was not significant in the sub-
group of patients diagnosed to have breast cancer during 
pregnancy compared to controls, however, patients 
diagnosed to have cancer in the post-partum period had 
a poor outcome compared to the controls [24]. Halaska 
et al. compared the presentations and outcomes of 32 
patients with PABC with matched controls and found 
the OS to be similar [15]. However, the sub-group of 16 
patients diagnosed to have cancer in the post-partum 
period had a shorter time to relapse than either the 
controls, compared to the patients diagnosed during 
pregnancy. On the other hand, the median DFS was 
70.6 months in women who started chemotherapy 
during pregnancy, compared with 94.4 months in 
women who received the entire chemotherapy treatment 
after delivery in a large observational study from seven 
European countries [16]. 
The effects of chemotherapy on the fetus were also 
studied.  The mean gestational age at delivery was 
35.6±1.6 (33-38) weeks; there was only one case of 
low birth weight, but no case of fetal malformation, or 
newborn complications. The mean APGAR score was 
almost 9 and 10 at 1 and 5 minutes. The prospective 
observational study from Europe suggests that the birth 
weight was lower for the infants who were exposed to 
chemotherapy after adjustment for gestational age, but 
was not influenced by the number of cycles received. 
Also, there were no significant differences in the birth 
weight of pre-term (less than 37 weeks of gestation) 
infant, whether or not they had been exposed to 
chemotherapy in utero. However, the pre-term infants 
were more likely to develop malformations and newborn 
complications [12, 16]. It has been suggested that the 
fetal complications were the result of premature delivery, 
rather than exposure to chemotherapy.
Two patients in our series developed a subsequent 
pregnancy after successful treatment of PABC. There is 
an ongoing debate about the safety of patients becoming 
pregnant in such circumstances. The major concerns 
are the occurrence of new cancer, recurrence of initial 
cancer, and decreased survival, especially for the ER-
positive tumors. Azim et al. compared the outcomes 
of patients who became pregnant after treatment of 
PABC with those who did not and found no difference 
in DFS, and even an improvement in the OS in those 
who became pregnant, in the small cohort of patients 
[26]. The results were further substantiated by Amant 
et al. who found similar OS between pregnant and non-
pregnant women with breast cancer [27].
CONCLUSION
We report long-term outcomes of patients with PABC 
from an Arabian country, where the fertility rate is high. 
Whereas the mean age at presentation was comparable 
to the published literature, biologically the disease 
was more aggressive, as suggested by a large tumor 
size, multifocal disease, fewer patients were ER/PgR 
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positive, and more patients were HER-2/neu positive, or 
triple-negative. Although the response to treatment was 
comparable, the long-term survival was inferior to the 
general population of comparable age. The study may 
help to set a benchmark for studies from the region. 
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